As of last check in afterhours trading, Acutus Medical Inc. (AFIB) was down -9.31% at $15.39. The Acutus stock price was almost stable on Friday, falling -0.12% to close the day at $16.97. AFIB stock volume was 43030.0, which is lower than the average volume over the past three months of 218.56K. The price of the AFIB stock fluctuated from $16.67 to $17.17 during this period.
AFIB reported earnings per share of -4.98 during the regular session. AFIB shares have lost -3.91% in the last five sessions, gained 6.26% over the past month, but lost -41.10% for the year. With a 50-day moving average of $15.13, AFIB stock is below its 200-day moving average of $21.84. Additionally, the AFIB stock’s RSI is currently 56.38.
When there has been no news about AFIB, it may be reasonable to expect recent developments to provide additional information.
AFIB, what has been happening recently?
Acutus manages cardiac arrhythmias and aims to improve the way these disorders are diagnosed and treated. Providing physicians with a superior range of products and technologies, the AFIB is dedicated to advancing the field of electrophysiology. AFIB has built an international sales network through internal product development, acquisitions, and global partnerships. AFIB’s products provide cardiac arrhythmia patients with a comprehensive solution for catheter-based treatment.
AcQBlate Force Sensing Ablation Catheter and System have recently been approved by the FDA for use in the company’s Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial, Acutus announced recently.
- AFIB focused on this trial as in the United States, there are approximately 190,000 ablation procedures annually.
- By 20251 that number is projected to reach 375,000.
- AFIB plans to enroll 350 patients at leading centers globally in a trial designed to evaluate the system’s effectiveness and safety in the treatment of persistent and paroxysmal atrial fibrillation.
- AcQBlate Force gold-tipped catheter and system by AFIB are designed specifically to provide consistent therapeutic solutions during cardiac ablation procedures.
- AFIB’s system enables physicians to view current contact force, in real-time, while performing ablations on the heart.
- Real-time contact force information has been shown to help physicians deliver safe and effective therapy to patients, thus improving their outcomes.
Achievements and strategies:
As of late 2020, Acutus (AFIB)’s advanced system has received a CE Mark, enabling it to become commercially available in Europe. AFIB’s Pulsed Field Ablation (PFA) program plans to use the AcQBlate Force Catheter and System in addition to US IDE and European commercial activities. Once participating sites gain necessary institutional review board (IRB) approvals, AFIB expects enrollment for its AcQBlate Force AF trial to commence in the second half of 2021.
